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Ribosome biogenesis has been associated with regulation of cell growth and cell division, but the molecular
mechanisms that integrate the effect of ribosome biogenesis on these processes in mammalian cells remain
unknown. To study the effect of impaired ribosome functions in vivo, we conditionally deleted one or two
alleles of the 40S ribosomal protein S6 gene in T cells in the mouse. While complete deletion of S6 abrogated
T-cell development, hemizygous expression did not have any effect on T-cell maturation in the thymus, but
inhibited the accumulation of T cells in the spleen and lymph nodes, as a result of their decreased survival in
the peripheral lymphoid organs. Additionally, TCR-mediated stimulation of S6-heterozygous T cells induced a
normal increase in their size, but cell cycle progression was impaired. Genetic inactivation of p53 tumor
suppressor rescued development of S6-homozygous null thymocytes and proliferative defect of
S6-heterozygous T cells. These results demonstrate the existence of a p53-dependent checkpoint mechanism
that senses changes in the fidelity of the translational machinery to prevent aberrant cell division or eliminate
defective T cells in vivo. Failure to activate this checkpoint response could potentially lead to a development
of pathological processes such as tumors and autoimmune diseases.
[Keywords: S6 ribosomal protein; ribosome biogenesis; cell growth; cell proliferation; checkpoint]
Supplemental material is available at http://www.genesdev.org.
Received July 14, 2005; revised version accepted October 25, 2005.
Cell growth (increase in cell mass) and cell division (in-
crease in cell number) are separable processes that are
coordinated in most dividing cells, probably to ensure
that there are sufficient cellular components for survival
and normal functioning of daughter cells (Conlon and
Raff 1999). Although earlier studies suggested a tight co-
ordination between cell growth and division, recent
analyses in higher organisms very often reveal their
loose coordination (Hartwell 1971; Nurse et al. 1976;
Zetterberg and Larsson 1991; Neufeld et al. 1998;
Stocker and Hafen 2000; Weinkove and Leevers 2000;
Conlon et al. 2001; Du and Stillman 2002; Jorgensen and
Tyers 2004; Sveiczer et al. 2004; O’Farrell et al. 2004).
Over the last few decades, major advances have been
made in understanding the machinery that controls pro-
gression through the cell division cycle, in particular
identifying cell cycle regulatory genes, including cyclins,
cyclin-dependent kinases, and their inhibitors, as well as
genes that monitor the distinct steps of cell cycle pro-
gression, termed cell cycle checkpoint genes (Elledge
1996; Sherr and Roberts 1999; Nurse 2000). A cell cycle
checkpoint is defined as a regulatory pathway that con-
trols the order and timing of cell cycle transitions, en-
suring that critical events such as DNA replication,
chromosome segregation, and probably many other
events are completed with high fidelity (Nurse 2000;
Jones et al. 2005). Mechanistically, cell cycle check-
points establish the relationship between two unrelated
biochemical events. The first represents the event in
which a lesion takes place, and the second prevents the
cell from progressing through the cell cycle until the first
event has been repaired. The establishment of this rela-
tionship requires the presence of three components: (1) a
defect (the lesion); (2) a sensor, which detects the defect;
and (3) a target, a cell cycle regulator. Failure to activate
these checkpoints allows a cell to divide when DNA is
damaged or when chromosomes are incorrectly parti-
tioned, leading to genomic instability. This is essential
for the generation of cancer, as evidenced by the high
frequency of mutations of cell cycle checkpoint genes in
human cancer (Nurse 2000).
On the other hand, it is poorly understood what cell
growth really is and how it is regulated (Conlon and Raff
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1999). Cell growth is regulated by growth-factor and nu-
trient activation of several signaling pathways that con-
trol anabolic processes (Schmelzle and Hall 2000; Vo-
larevic and Thomas 2001; Hafen 2004; Holland et al.
2004). Genetic analyses in Drosophila melanogaster had
discovered that Ras, Myc, and PI3K–TOR signaling cas-
cades regulate cell growth (Johnston et al. 1999; Wein-
kove et al. 1999; Prober and Edgar 2000; Johnston and
Gallant 2002). It has been proposed that protein synthesis
may be a key determinant of cell growth (Pardee 1989).
Consistent with this, the Myc, Ras, and PI3K–TOR sig-
naling pathways increase the overall rate of protein syn-
thesis by stimulating either the rates of translation ini-
tiation and elongation or ribosome biogenesis (Holland
et al. 2004). It has been suggested that deregulation of the
molecular mechanisms controlling cell growth results in
cells of altered size and can contribute to a variety of
pathological conditions, including cancer (Holland et al.
2004). More than 30 years ago, Harvey Lodish postulated
that the spectrum of translated mRNA varies with the
overall rate of protein synthesis (Lodish 1974). Messen-
ger RNAs that have low affinity for translational ma-
chinery are outcompeted with messages with high affin-
ity when the rate of translation is reduced, whereas low-
and high-affinity mRNAs are translated when protein
synthesis becomes up-regulated, as in the case of hyper-
activation of growth stimulating pathways (Rajasekhar
et al. 2003; Mamane et al. 2004). The fact that many
mRNAs with low affinity for the translational machin-
ery encode many oncoproteins, growth factors, survival
factors, and cell cycle regulators, suggests that a non-
physiological increase in the rate of translation, as the
result of deregulation of growth signaling pathways, and
could cause malignant transformation. This notion is
further supported by the discovery that rapamycin, an
effective anticancer drug, inhibits a key regulator of pro-
tein synthetic machinery and cell growth, mTORC1
(Holland et al. 2004).
As mentioned above, the synthesis of proteins during
cell growth and proliferation requires ribosome biogen-
esis (Thomas 2000; Warner et al. 2001). Genes that con-
trol ribosome biogenesis and protein translation have
been identified in yeast as critical regulators of cell
growth and cell size (Jorgensen et al. 2002; Jorgensen and
Tyers 2004; Zhang et al. 2002). Ribosome biogenesis is
one of the major energy-consuming processes in prolif-
erating cells (Hadjiolov 1985; Lewis and Tollervey 2000;
Thomas 2000; Warner et al. 2001; Fatica and Tollervey
2002; Moss 2004).
Given the enormous energy investment in ribosome
biogenesis, its importance to cell growth and prolifera-
tion, and the observation that some human diseases are
caused by defects in ribosome biogenesis, we and others
had hypothesized that the mechanisms must have
evolved to sense the fidelity of this process (Draptchin-
skaia et al. 1999; Volarevic et al. 2000; Ruggero and Pan-
dolfi 2003; Holland et al. 2004; Olson 2004).
To discover such molecular mechanisms in a geneti-
cally defined in vivo mouse model, we induced a defect
in this process by deleting one or both alleles of S6 ribo-
somal protein gene in the thymus by using CD4-Cre
transgenic mice (Sawada et al. 1994; Wolfer et al. 2001).
T lymphocytes are ideal for studying the relationship
between ribosome biogenesis, cell growth, and prolifera-
tion since the initial response of T cells to antigenic
stimulation is transformation of small resting cells into
large blasts, followed by cell division (Rathmell et al.
2000; Frauwirth et al. 2002). Additionally, a long-term
consequence of a defect in ribosome biogenesis could be
followed in several experimental paradigms in vivo. In
this report we show that in T-cell receptor (TCR)-stimu-
lated T cells, fidelity of ribosome biogenesis is moni-
tored by a p53-dependent checkpoint regulatory pathway
that inhibits cell division or induces apoptosis of poten-
tially defective cells.
Results
Specific deletion of the S6 gene in the thymus
To generate a model for studying the effects of decreased
S6 expression on development and function of T cells,
we decided to delete both alleles of the S6 ribosomal
gene in the thymus by using mice that express the Cre
recombinase under the control of a CD4 promoter
(Sawada et al. 1994; Wolfer et al. 2001). The CD4 pro-
moter directs the expression of Cre recombinase in CD4+
CD8+ thymocytes, and, to a lesser extent, in CD4− CD8−
thymocytes. The thymi from 57% of S6lox/lox/CD4-Cre+
mice could not be recovered (n = 23), and ones that were
recovered manifested on average a 100-fold decreases in
the cell number relative to S6lox/lox/CD4-Cre− control
mice (Fig. 1A). Southern blot analysis of genomic DNA
from pooled thymi showed that deletion of S6 is com-
plete (Fig. 1B). These data demonstrate that S6 is abso-
lutely required for T-cell development.
Next, we decided to conditionally delete only one S6
allele in the thymus. The extent of S6 deletion in thymi
from S6wt/lox/CD4-Cre+ mice was determined by South-
ern blot analysis. The blot revealed the expected 9.1-kb
band, representing the S6 fragment after Cre-mediated
recombination, and the absence of the 4.6-kb S6lox band,
showing that deletion of the floxed S6 allele was com-
plete (Fig. 1C). There was no effect on the wild-type S6
allele. To examine the effect of a single S6 allele deletion
on S6 mRNA expression, total RNA from S6wt/lox/CD4-
Cre+ thymi was analyzed by Northern blot using the
S6-specific probe. S6wt/lox thymi contained easily detect-
able S6 mRNA. S6wt/del thymi showed ∼50% decrease in
S6 mRNA expression relative to control thymi (Fig. 1D).
Therefore, the remaining S6 allele cannot compensate
for the loss of the other allele at the level of S6 mRNA in
thymocytes. To examine the consequences of a condi-
tional S6wt/del mutation on thymocyte development, we
purified thymocytes from S6wt/lox/CD4-Cre+ mice, and
determined their cellularity and subset representation.
The total number of thymocytes in 4-wk-old S6wt/lox/
CD4-Cre+ mice was similar to that of S6wt/lox/CD4-Cre−
controls (Fig. 1E). FACS analysis of cells from S6wt/del
thymi revealed that T-cell populations defined by CD4,
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CD8, and CD3 markers were also normal (Fig. 1F). Also,
analysis of mutant CD4− CD8−, CD4+ CD8+, CD4+, and
CD8+ populations of thymocytes with FACS confirmed
that their size as measured by forward light scatter (FSC)
was similar to the size of corresponding populations of
control thymocytes (data not shown). In agreement with
normal phenotype, the protein expression of S6 in
S6wt/del thymi was indistinguishable from the control,
suggesting that one S6 allele is sufficient to support nor-
mal S6 protein production during T-cell development
(Fig. 1G). Consistent with these results is the observa-
tion that the amount of mature 18S and 28S rRNAs in
mutant and control thymocytes was indistinguishable
(Fig. 1H). These results suggest that T-cell development
is unperturbed by conditional deletion of one S6 allele.
Effects of S6 heterozygous deletion in peripheral
lymphoid organs
We next wanted to determine if deletion of one S6 allele
has an effect on T-cell peripheral compartments in
spleen and lymph nodes. The total number of spleno-
cytes was decreased by 14% in male and 23% in female
4-wk-old S6wt/lox/Cre+ mice compared with S6wt/lox/
Cre− controls (Fig. 2A). The percentage of T cells in the
spleen was reduced from 21% in control mice to 9% in
S6wt/lox/Cre+ mice (Fig. 2B; data not shown). When total
splenic cell number was taken into account, S6wt/lox/
CD4-Cre+ mice exhibited an even larger decrease of
∼60%–65%in the total number of T cells.
The percentage of T cells in lymph nodes from S6wt/lox/
CD4-Cre+ mice was reduced by ∼25% (Fig. 2C; data
not shown). Interestingly, while a decreased number of
T cells in the spleen resulted from loss of both CD4 and
CD8 T-cell subsets (Fig. 2D), a decrease in the number of
T cells in lymph nodes was mainly due to the reduction
in CD8 cells (Fig. 2E). Similar reductions in the number
of splenic and lymph node T cells were also observed in
1-, 2-, 3-, 5-, 6-, 7-, and 8-wk-old S6wt/lox/CD4-Cre+ mice
(data not shown).
To exclude the possibility that the remaining T cells
in the periphery are those in which Cre-mediated recom-
bination was ineffective, Southern blot analysis of S6
alleles in purified T cells from lymph nodes was per-
formed, and it revealed that all S6wt/lox/CD4-Cre+ lymph
node T cells have an S6wt/del genotype (Fig. 2F). The
similar results were obtained when genomic DNA from
purified splenic T cells was analyzed for the presence of
S6 alleles (data not shown). Forward light scatter analysis
(FSC) of CD3, CD4, and CD8 positive cells from spleen
and lymph nodes of S6wt/del T cells revealed their normal
size (data not shown). These results indicate that condi-
tional deletion of one allele of S6 has a substantial effect
on the number of mature T cells in the periphery, while
there was no effect on the cell size of resting T cells. To
determine whether the number of mutant T cells in the
secondary lymphoid organs is affected by homeostatic
proliferation, we assessed the proliferative activity of
T cells from S6wt/lox/CD4-Cre+ and S6wt/lox/CD4-Cre−
mice following in vivo labeling with BrdU for 7 d, start-
Figure 1. Conditional deletion of the S6 gene in
the thymus. (A) Total number of thymocytes in
S6lox/lox/CD4-Cre− and S6lox/lox/CD4-Cre+ mice
(n = 14 and 10, respectively). (B) Southern blot
analysis of genomic DNA from pooled thymi of
S6lox/lox/CD4-Cre+ and S6lox/lox/CD4-Cre− mice
using S6 intron-specific probe. The positions of
DNA fragments representing S6del and S6lox are
shown. (C) Southern blot analysis of genomic
DNA from S6wt/lox/CD4-Cre− and S6wt/lox/CD4-
Cre+ thymi using S6 intron-specific probe. The
positions of DNA fragments representing S6del,
S6lox, and S6wt alleles are indicated. (D) Northern
blot analysis of total RNA from S6wt/lox/CD4-
Cre− and S6wt/lox/CD4-Cre+ thymi using S6
cDNA as a probe. The L11 cDNA probe was used
as a control for loading the same quantity of total
RNA on the gel. (E) Total number of thymocytes
from S6wt/lox/CD4-Cre− and S6wt/lox/CD4-Cre+
mice. (F) S6wt/lox/CD4-Cre− and S6wt/lox/CD4-
Cre+ thymocytes were stained with CD4 and CD8
antibodies (left panel) or anti-CD3 antibodies
(right panel), and analyzed by FACS. Cell surface
markers are shown as coordinates. The numbers
in the quadrant refer to the percentage of a par-
ticular T-cell population of live cells. (G) The pro-
tein expression of ribosomal proteins S6, L7a, and
L11 in thymocytes from S6wt/lox/CD4-Cre+ and
S6wt/lox/CD4-Cre− mice was analyzed by Western blot. Reprobing with antibodies to actin served as a loading control. (H) Total RNA
from 15 × 106 S6wt/lox/CD4-Cre+ and S6wt/lox/CD4-Cre− thymocytes was separated in agarose gel containing formaldehyde, transferred
to a nitrocellulose membrane, and stained with ethidium bromide. Positions of 28S and 18S rRNAs are shown.
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ing at 6 wk of age. A similar percentage of labeled T cells
was seen in both groups, indicating that the observed
phenotype is not the result of slower homeostatic pro-
liferation (Fig. 2G). Next, we set out to determine
S6wt/del T-cell survival in vivo. Resting S6wt/del and
S6wt/lox T cells were labeled with 5-6-carboxyfluorescein
diacetate succinimidyl ester (CFSE) and then separately
transferred into nonradiated syngenic wild-type hosts.
The percentage of CFSE-labeled T cells was determined
in the spleen and lymph nodes after 3 d by FACS analy-
sis. The fraction of CFSE-labeled T cells in both spleen
and lymph nodes was >50% lower in mice receiving
S6wt/del than in mice receiving S6wt/lox T cells, indicat-
ing that mutant T cells have a shorter life span (Fig. 2H).
The expression of the Eµ-bcl-2-36 transgene in S6wt/del
T cells partially rescued their decreased number in the
spleen, suggesting that increased Bcl-2-dependent apo-
ptosis contributes to the phenotype (Strasser et al. 1994;
Supplementary Fig. 1).
Inactivation of one S6 allele inhibits ribosome
biogenesis, but not T-cell growth
Following T-cell receptor stimulation, T cells increase in
size before they enter the S phase of the cell cycle. To
determine if S6wt/del T cells can mount this response, we
stimulated these cells with anti-CD3 and anti-CD28 an-
tibodies and measured forward light scatter parameter by
flow cytometry at 25, 30, and 35 h following stimulation.
There was no difference in kinetics or extent of cell
growth between control and mutant T cells (Fig. 3A).
The effect of the S6wt/del mutation on the protein ex-
pression of S6 in resting and stimulated T cells was de-
termined by Western blot (Fig. 3B). S6wt/del and S6wt/lox
T cells were analyzed unstimulated (0-h time point) or
were analyzed following stimulation with anti-CD3 and
anti-CD28 antibodies for 24 or 36 h. In unstimulated
mutant and control T cells, the levels of S6 protein were
indistinguishable, suggesting that one S6 allele is suffi-
cient to support normal S6 protein production under
such conditions. The S6 protein levels were substan-
tially lower in stimulated S6wt/del T cells than in control,
at 24 and 36 h following stimulation. In contrast, ribo-
somal protein L7a was produced at similar levels in
stimulated mutant and control T cells. Since S6 ribo-
somal protein is an essential 40S ribosomal protein, and
T-cell activation is accompanied by significant ribosome
biogenesis, we wanted to determine whether deletion of
one S6 allele in T cells affects this process (Fig. 3C).
S6wt/del T cells were first stimulated with the combina-
tion of anti-CD3 and anti-CD28 antibodies for 20 h, then
labeled with L-[methyl-3H]-methionine for 30 min and
chased for indicated time periods. After 15 min, pre-
sumed 34S rRNA precursor accumulated in higher
amounts in the mutant than in control T cells, suggest-
ing an rRNA processing defect. At the 30-min time
point, the S6wt/del mutation reduced 18S but not 28S
rRNA labeling, while at the 45-min time point, a de-
Figure 2. Decreased number of S6wt/del T cells
in the spleen and lymph nodes is a conse-
quence of their decreased survival. (A) Total
cell number in spleens from female (F) and
male (M) S6wt/lox/CD4-Cre− and S6wt/lox/CD4-
Cre+ mice (n = 10, for each group). Error bars
represent standard deviation. For females, (*)
p < 0.05 versus S6wt/lox/CD4-Cre− splenocytes;
and for males, (**) p > 0.05 versus S6wt/lox/
CD4-Cre− splenocytes (Mann Whitney U-test).
(B,D) FACS analysis of cells from S6wt/lox/
CD4-Cre− and S6wt/lox/CD4-Cre+ spleens. (C,E)
FACS analysis of cells from S6wt/lox/CD4-Cre−
and S6wt/lox/CD4-Cre+ lymph nodes (n = 35, for
each group). (*) p < 0.001 versus S6wt/lox/CD4-
Cre− CD3+ cells (t-test). Genotypes are as indi-
cated above the panels. Cell surface markers
are shown as coordinates. The numbers in
quadrants refer to percentage of respective cell
population of live cells. (F) Southern blot
analysis of genomic DNA from S6wt/lox/CD4-
Cre− and S6wt/lox/CD4-Cre+ T cells purified
from lymph nodes of 8-wk-old mice using the
S6 intron-specific probe. (G) Six-week-old S6wt/
lox/CD4-Cre− and S6wt/lox/CD4-Cre+ mice were
daily injected intraperitoneally with 100 µg/g
of body weight 5-BrdU (Sigma) in 200 µL of PBS
during the indicated time periods; 5-BrdU incorporation into DNA was determined by flow cytometry. The percentages of 5-BrdU-
positive lymph node T cells are shown. The experiment is a representative of four independent experiments. (H) CFSE-labeled
S6wt/lox/CD4-Cre+ or S6wt/lox/CD4-Cre+ T cells (10 × 106) were transferred into wild-type recipients by intravenous injection, and the
percentage of CFSE-labeled T cells was determined in spleens. The total number of T cells in different recipients was similar. The
experiment is a representative of three independent experiments.
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crease in the amount of both 18S and 28S rRNA was
observed in S6wt/del T cells, which closely reflects the
amount of 40S and 60S ribosomal subunits, respectively.
This is consistent with the decreased S6 protein levels in
stimulated T cells shown in Figure 3B. Thus, conditional
deletion of one S6 allele in stimulated T cells decreases
the amount of both, 18S and 28S rRNA. Interestingly,
the synthesis of ribosomal protein L7a continues nor-
mally.
The fact that TCR-stimulated cell growth was normal
in S6wt/del T cells, even though ribosome biogenesis is
affected, led us to investigate their general protein syn-
thetic capacity (Fig. 3D). We compared the total cellular
protein content per 1 × 106 of S6wt/lox and S6wt/del T cells
prior to TCR/CD28 activation and 24 h after stimula-
tion. There was no significant difference in the total cel-
lular protein content in unstimulated or stimulated mu-
tant and control T cells. These results suggest that a
smaller number of ribosomes in S6wt/del T cells is suffi-
cient for normal TCR/CD28-stimulated cell growth.
Analysis of proliferative defects in S6 heterozygous
T cells
Although deletion of one allele of the S6 gene had no
effect on TCR-stimulated cell growth, it was interesting
to test the effects of an S6wt/del mutation on T-cell pro-
liferation. Purified lymph node T cells from wild-type
and mutant mice were stimulated with 0.1 µg/mL (open
symbols) or 1 µg/mL (closed symbols) anti-CD3 and with
a constant concentration of anti-CD28 antibodies (0.1
µg/mL) in vitro, and the relative number of live T cells
was determined at 24, 48, and 72 h thereafter (Fig. 4A).
The number of both control and mutant T cells de-
creased during the first 24 h of stimulation. There was a
small increase in the number of S6wt/lox T cells at 48 h,
while the dramatic increase was observed after 72 h of
stimulation with either concentration of anti-CD3 anti-
bodies. In contrast, no change in the number of S6wt/del
T cells was seen after the initial drop that was observed
at 24 h after stimulation.
To understand how the S6wt/del mutation impairs
TCR- and CD28-induced proliferation, we first analyzed
activation events that precede cell cycle progression.
Since proliferation of T cells is mediated by the interac-
tion of IL-2 with the IL-2 receptor, we first analyzed the
kinetics of their expression levels following stimulation
with anti-TCR and anti-CD28 antibodies by flow cytom-
etry (Fig. 4B). Despite dramatic differences in cell num-
bers after 48 or 72 h of stimulation, expression of IL-2
receptor and IL-2 following TCR and CD28 stimulation
of T cells of the different genotypes was similar. Further-
more, TCR and CD28 stimulation induced equivalent
increases in the expression of the activation marker
CD69 and IFN- in mutant and control T cells (Fig. 4B).
We also examined proliferation of mutant and control T
cells in response to the exogenous IL-2 (Fig. 4C). Both
cell types were stimulated with anti-CD3 antibodies in
the absence of CD28 costimulation. Such treatment in-
duced a similar level of the IL-2 receptor expression but
did not induce IL-2 production and T-cell proliferation
(data not shown). When a saturating concentration of
IL-2 containing MLA-144 supernatant was added to
these cultures, increases in the cell number were seen in
S6wt/lox but not in S6wt/del T cells. These results suggest
that proximal TCR signaling pathways are similar in
S6wt/lox and S6wt/del T cells and that the S6wt/del muta-
tion interferes with T-cell proliferation downstream of
the IL-2 receptor.
The inability of stimulated S6wt/del T cells to prolifer-
ate could arise from impaired cell division, increased cell
death, or both. We first analyzed division of individual
Figure 3. T-cell receptor-stimulated ribosome biogen-
esis is decreased in S6wt/del T cells, but their growth is
normal. (A) FSC analysis of S6wt/lox and S6wt/del lymph
node T cells stimulated with soluble 1 µg/mL anti-CD3
and 0.1 µg/mL anti-CD28 in vitro was used to deter-
mine their size. (B) The protein expression of ribosomal
proteins S6 and L7a in lysates from unstimulated (0 h)
and stimulated (24 and 36 h) lymph node S6wt/del and
S6wt/lox T cells was analyzed by Western blot. Reprob-
ing with antibodies to actin served as a loading control.
(C) To gain insight into rRNA processing, S6wt/del and
S6wt/lox T cells were stimulated for 20 h with TCR and
CD28 antibodies, pulse-labeled with L-[methyl-3H]me-
thionine for 30 min, and chased in nonradioactive me-
dium for the indicated time. Total RNA normalized to
equal cell number was resolved on a formaldehyde-aga-
rose gel, transferred to a nylon membrane, and visual-
ized by autoradiography. The positions of major precur-
sors and 28S and 18S rRNA species are indicated on the
left. The experiment is a representative of five indepen-
dent experiments. (D) Total cellular protein content per
1 × 106 S6wt/lox or S6wt/del lymph node T cells before
stimulation and after 24 h of stimulation with antibod-
ies against TCR and CD28. The experiment is a repre-
sentative of six independent experiments.
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S6wt/lox and S6wt/del T cells using CFSE labeling. This
method is based on the approximately twofold decreases
in CFSE fluorescence after each cell division. Lymph
node T cells of the indicated genotype were labeled with
CFSE and stimulated, as before, with different concen-
trations of anti-TCR and anti-CD28 antibodies for 48 or
72 h, and CFSE fluorescence was determined by flow
cytometry (Fig. 4D). The majority of stimulated control
cells progressed trough three to four divisions after 48 h.
In contrast, the majority of mutant T cells did not pro-
liferate at all during the same period, and those that did
progressed through only one division. Analysis of CFSE
fluorescence at 72 h following stimulation revealed that
the proportion of mutant T cells remained undivided,
while the rest went through a small number of divisions.
In contrast, all control T cells progressed through three
to six divisions. These data indicate that deletion of one
S6 allele dramatically decreases both the percentage of T
cells that proliferates in response to stimulation with
anti-CD3 and anti-CD28 and the extent of proliferation.
Southern blot analysis of DNA isolated from mutant T-
cell culture at 72 h following stimulation confirmed the
presence of S6wt/del T cells and the absence of T cells
that did not delete one floxed S6 allele (Fig. 4E).
To determine why the doubling time of S6wt/del T cells
is increased, we determined the percentage of mutant
and control T cells that enter S phase at 2-h intervals,
from 16 to 26 h after stimulation, by measuring BrdU
incorporation using flow cytometry (Fig. 5A). The num-
ber of control T cells that enter S phase was much greater
than the number of mutant cells at all time points. Thus,
the deletion of one S6 allele in T cells results in G1/S cell
cycle block. Passage through the cell cycle requires
timely modulation of activities of the cell cycle regula-
tors. Cell cycle progression can be inhibited by cyclin-
dependent kinase inhibitors. To determine the molecu-
lar mechanism of the proliferative defect in S6wt/del T
cells, we first analyzed the protein expression levels of
p21 inhibitor at different time points following TCR
stimulation (Fig. 5B). In unstimulated mutant and con-
trol T cells, p21 protein was undetectable. At 24 h after
stimulation, the protein levels of p21 were up-regulated
in mutant T cells but not in the control. At 36 h after
stimulation, p21 protein levels were significantly higher
in S6wt/del T cells than in the control. These results sug-
gest that p21 induction could be responsible for a slower
cell cycle of S6wt/del T cells and their inability to prolif-
erate following stimulation.
To investigate whether apoptosis also contributes to
the failure of S6wt/del T cells to increase in numbers fol-
lowing stimulation, mutant and control T cells were
stimulated through TCR/CD28 for 24, 48, and 72 h and
stained with propidium iodide, and DNA content was
analyzed by flow cytometry (Fig. 5C). Cells having sub-
G1 DNA content were considered to be apoptotic. A
slightly higher percentage of S6wt/del than S6wt/lox T cells
was apoptotic at all tested time points following TCR/
CD28 stimulation. It is well known that anti-apoptotic
protein Bcl-2 can inhibit some forms of apoptotic cell
death (Strasser et al. 1994). The Bcl-2 transgene was in-
troduced into S6wt/lox/CD4-Cre+ and S6wt/lox/CD4-Cre−
mice by appropriate breeding (Strasser et al. 1994). In the
Figure 4. Stimulation of S6wt/del T cells does
not increase their cell number. (A) Relative
number of S6wt/lox and S6wt/del T cells stimu-
lated with either 0.1 µg (open symbols) or 1
µg/mL (closed symbols) of anti-CD3 and fixed
concentration of anti-CD28 antibodies (0.1
µg/mL) during 72 h in vitro. The experiment
is a representative of 15 independent experi-
ments. (B) FACS analysis of expression levels
of CD25, intracellular IL-2, and IFN- in
S6wt/lox and S6wt/del lymph node T cells
stimulated for the indicated period of time in
vitro. (C) Relative number of S6wt/lox and
S6wt/del lymph node T cells stimulated with
soluble anti-CD3 antibodies and saturating
concentration of IL-2 containing MLA-144 su-
pernatant (1:2 dilution). The experiment is a
representative of three independent experi-
ments. (D) FACS analysis of lymph node T
cells that were stimulated with different con-
centrations of anti-CD3 (1 µg/mL, upper
panel; 0.1 µg/mL, lower panel) and anti-CD28
antibodies (0.1 µg/mL) and labeled with CFSE.
The filled area represents CFSE labeling of T
cells before they divided for the first time.
The number of cell divisions is indicated
above the peaks. (E) Southern blot analysis of
genomic DNA from S6wt/lox and S6wt/del
lymph node T-cell cultures at 72 h following
stimulation.
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presence of the anti-apoptotic Bcl-2 transgene, apoptosis
was similar in TCR/CD28-stimulated S6wt/del and
S6wt/lox T cells (Fig. 5C). Therefore, apoptosis contrib-
utes to the failure of S6wt/del T cells to proliferate after
stimulation, and this defect can partially be reversed by
anti-apoptotic protein Bcl-2.
To determine a relative contribution of apoptosis to
the failure of mutant T cells to increase their numbers in
response to TCR stimulation, S6wt/lox, S6wt/del, S6wt/lox/
Bcl-2+, and S6wt/del/Bcl-2+ T cells were stimulated with
the combination of anti-TCR and anti-CD28 antibodies
in vitro for 24, 48, and 72 h. Even though apoptosis was
similar in mutant and control T cells in the presence of
the Bcl-2 transgene (Fig. 5C), increases in the cell numbers
were only weakly rescued in mutant T cells (Fig. 5D).
These results show that the inability of S6wt/del T cells
to proliferate following TCR-mediated stimulation is
due to induction of G1/S cell cycle block and partially to
increased apoptosis.
S6 inactivation induces a p53-dependent checkpoint
response
The cell cycle inhibitor p21 is a transcriptional target of
the p53 tumor suppressor. In addition to inhibition of
cell cycle progression through induction of p21, p53 pro-
tein may induce apoptotic cell death (Vousden 2002). To
examine the role of p53 in the observed in vivo and in
vitro phenotypes, we decided to delete both flox alleles
of p53 in combination with one or two floxed S6 alleles
in the thymus using CD4-Cre transgenic mice (Sawada
et al. 1994; Marino et al. 2000; Wolfer et al. 2001). Analy-
sis of S6 and p53 alleles in thymi and peripheral T cells
from compound S6wt/lox/p53lox/lox/CD4-Cre+ mice con-
firmed that S6lox and p53lox alleles are efficiently code-
leted (Supplementary Fig. 2).
First, we set out to determine whether p53 deletion
could correct the decreased number of S6wt/del T cells in
the spleen. As shown in Figure 2, the number and pro-
portion of T cells in the spleen from 4-wk-old S6wt/lox/
CD4-Cre+ mice were significantly lower than in S6wt/lox/
CD4-Cre− mice. However, the percentages (Fig. 6A) and
total number (Fig. 6B) of T cells in spleens from S6wt/lox/
p53lox/lox/CD4-Cre+ and S6wt/wt/p53lox/lox/CD4-Cre+
were similar, indicating that p53 is responsible for the
decreased number of S6 heterozygous T cells in vivo.
To test if homozygous deletion of p53 can rescue the
proliferative defect of S6 heterozygous T cells, S6wt/lox/
CD4-Cre+, S6wt/wt/p53lox/lox/CD4-Cre+, and S6wt/lox/
p53lox/lox/CD4-Cre+ were stimulated with anti-CD3 an-
tibodies and anti-CD28 antibodies for 24, 48, and 72 h
(Fig. 6C). Consistent with the results already shown,
S6wt/lox/CD4-Cre+ T cells did not proliferate. In contrast,
p53 inactivation almost completely rescued the prolif-
erative defect of stimulated S6wt/lox/CD4-Cre+ T cells.
Also, the percentage of apoptotic S6wt/wt/p53lox/lox/CD4-
Cre+ and S6wt/lox/p53lox/lox/CD4-Cre+ T cells was simi-
lar at all tested time points following TCR/CD28 stimu-
lation (data not shown). These results strongly suggest
that a defect in ribosome biogenesis, induced by S6 in-
activation, activates a p53-dependent checkpoint to pre-
vent survival and expansion of defective T cells.
The thymi from the majority of S6lox/lox/CD4-Cre+
mice could not be recovered, and ones that were recov-
ered manifested 100-fold decreases in the cell number
relative to S6lox/lox/CD4-Cre− control mice (Fig. 1A). Sur-
prisingly, inactivation of p53 gene completely rescued
S6lox/lox/CD4-Cre+ thymocyte numbers (Fig. 6D). Also,
FACS analysis of cells from S6lox/lox/p53lox/lox/CD4-Cre+
thymi revealed that T-cell populations defined by CD4,
CD8 markers were essentially similar to control S6wt/wt/
p53lox/lox/CD4-Cre+ thymi, except for a small decrease
in the percentage of CD8 positive thymocytes (Fig. 6E).
These results suggest that ribosomes synthesized before
S6 deletion are sufficient to allow development of
S6lox/lox/p53lox/lox/CD4-Cre+ T cells, and that inactiva-
tion of both S6 alleles abrogates T-cell development by
activating a p53-dependent checkpoint.
Figure 5. Defect in proliferation of S6wt/del T cells is
due to p21-induced G1/S block. (A) BrdU incorporation
into lymph node T cells stimulated with anti-CD3- and
IL-2-containing MLA144 supernatant in vitro. The ex-
periment is a representative of four independent experi-
ments. (B) The protein expression of p21 cell cycle in-
hibitor in lysates from resting and stimulated lymph
node S6wt/del and S6wt/lox T cells was analyzed by West-
ern blot. Reprobing with antibodies to actin served as a
loading control. (C) T cells of indicated genotypes were
stimulated for the indicated period of time, labeled with
propidium iodide, and analyzed by FACS. The percent-
age of apoptotic cells was determined by analyzing sub-
G1 DNA content. The experiment is a representative of
four independent experiments. (D) Relative number of
S6wt/lox, S6wt/del, S6wt/lox/Bcl-2+, and S6wt/del/Bcl-2+ T
cells stimulated with anti-CD3 and anti-CD28 antibod-
ies for 24, 48, and 72 h. The experiment is a represen-
tative of three independent experiments.
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To gain insight into the molecular mechanisms of p53
action in S6del/del thymocytes, we compared thymi from
S6lox/lox/Bcl-2+/CD4-Cre+ and S6lox/lox/Bcl-2+/CD4-Cre−
mice. The Bcl-2 transgene partially rescued a number of
S6lox/lox/CD4-Cre+ thymocytes (Fig. 6D). The Bcl-2
transgene is expressed in CD4− CD8−, CD4+ CD8+,
CD4+, and CD8+ thymocytes, and mature T cells. The
CD4 promoter directs the expression of Cre recombinase
in CD4+ CD8+, and to a lesser extent, in CD4− CD8−
thymocytes. This argues against the possibility that thy-
mocyte numbers in S6lox/lox/CD4-Cre+ mice are not
completely rescued by the Bcl-2 transgene because of its
delayed expression relative to CD4-Cre (Strasser et al.
1994). Additionally, FACS analysis revealed a small in-
crease in the percentage of CD4+ CD8+ thymocytes and
a decrease in CD4+ and CD8+ thymocytes, which is con-
sistent with partial block in transition between double
positive to single positive thymocytes (Fig. 6E). These
results suggest that proapoptotic proteins that can be
inhibited by Bcl-2 are p53 effectors in mediating a check-
point response in S6lox/lox/CD4-Cre+ thymocytes, and
they point to Bcl-2-independent p53 effectors.
Negligible numbers of S6lox/lox/p53lox/lox/CD4-Cre+
and S6lox/lox/Bcl-2+/CD4-Cre+ T cells were found in pe-
ripheral lymphoid organs, suggesting that ribosome bio-
genesis is necessary for their homeostatic expansion and
survival (data not shown).
Discussion
In this study we conditionally deleted the S6 ribosomal
protein gene in the thymus. Homozygous deletion of S6
induced a p53-dependent checkpoint response that abol-
ished T-cell development. In contrast, heterozygous S6
deletion did not have any effect on T-cell development
and TCR-stimulated cell growth response, but it de-
creased survival of T cells in the peripheral lymphoid
organs and inhibited TCR-mediated increases in T-cell
numbers in a p53-dependent manner.
The requirement for S6 in ribosome biogenesis
Conditional deletion of both S6 alleles in the liver using
the interferon -inducible Cre–loxP system abolished
biogenesis of the 40S ribosomal subunit with no effect
on the 60S ribosomal subunit (Volarevic et al. 2000).
These results suggested that S6 is an essential compo-
nent of the mouse ribosome. Here, we show that hetero-
zygous deletion of S6 does not have any effect on the
amount of 18S and 28S rRNA in the thymus, which
closely reflects the amount of 40S and 60S ribosomal
subunit, respectively. In parallel, the protein levels of S6
were normal, even though the amount of S6 mRNA was
decreased by ∼50%. These findings suggest that one al-
lele is sufficient to allow normal S6 protein production
and ribosome biogenesis in developing thymus, explain-
ing normal T-cell development.
The rate of ribosome biogenesis is very low in resting
T cells. Activation of T cells induces ribosome biogen-
esis and increases protein output, causing T cells to grow
rapidly within the first 24 h, and this growth phase is
followed by a proliferative phase and increase in cell
number (Rathmell et al. 2000; Frauwirth et al. 2002).
Under such conditions, deletion of one S6 allele limits
ribosome biogenesis in T cells.
Figure 6. A p53-dependent checkpoint is activated
following inactivation of one or two S6 alleles in T
cells. The percentage (A) and total number (B) of T
cells in spleens from S6wt/lox/CD4-Cre− (line 1),
S6wt/lox/CD4-Cre+ (line 2), S6wt/wt/p53lox/lox/CD4-
Cre+ (line 3), and S6wt/lox/p53lox/lox/CD4-Cre+ (line
4) 7-wk-old mice (n = 12 mice per each genotype). (C)
Relative number of S6wt/lox/CD4-Cre+, S6wtwt/
p53lox/lox/CD4-Cre+, and S6wt/lox/p53lox/lox/CD4-
Cre+ T cells at 24, 48, and 72 h after stimulation
with either 0.3 µg/mL (open symbols) or 1 µg/mL
(closed symbols) of anti-CD3 and fixed concentra-
tion of anti-CD28 antibodies (0.1 µg/mL). The ex-
periment is a representative of six independent ex-
periments. (D) Total number of cells in thymi from
S6lox/lox/CD4-Cre− (line 1), S6lox/lox/CD4-Cre+ (line
2), S6wt/wt/p53lox/lox/CD4-Cre+ (line 3), S6lox/lox/
p53lox/lox/CD4-Cre+ (line 4), S6lox/lox/Bcl-2+/CD4-
Cre− (line 5), and S6lox/lox/Bcl-2+/CD4-Cre+ (line 6)
mice (n = 10 mice per each genotype). (E) S6wt/wt/
p53lox/lox/CD4-Cre+, S6lox/lox/p53lox/lox/CD4-Cre+,
S6lox/lox/Bcl-2+/CD4-Cre−, and S6lox/lox/Bcl-2+/CD4-
Cre+ thymocytes were stained with anti-CD4 and
anti-CD8 antibodies, and analyzed by FACS. Cell
surface markers are shown as coordinates. The num-
bers in the quadrant refer to the percentage of a par-
ticular T-cell population of live cells.
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Survival of mature S6 heterozygous T cells is impaired
Maturation of S6 heterozygous T cells in the thymus was
normal, but the number of T cells in the spleen and
lymph nodes was reduced. The number of T cells in the
periphery in addition to the production in the thymus
depends on the homeostatic T-cell proliferation and T-
cell survival. Homeostatic proliferation of S6 heterozy-
gous T cells was comparable to the control. This result
suggests that one allele of S6 is sufficient to support rela-
tively normal production of S6 protein and ribosome bio-
genesis during this slow proliferative response. The de-
creased number of mature T cells in S6 heterozygous
mice is a result of p53 activation, as p53 inactivation
restored normal T-cell numbers in the periphery. Bcl-2
transgene partially rescued the number of T cells in the
spleen of S6wt/lox/CD4-Cre+ mice. These results show
that p53/Bcl-2-dependent apoptosis contributes to a de-
creased number of S6wt/del T cells in the spleen. Bcl-2-
independent p53 effectors could also regulate apoptosis
of S6wt/del T cells in the periphery. However, we cannot
formally rule out the possibility that decreased expan-
sion of S6wt/del T cells contributes as well.
Normal T-cell growth and impaired proliferation
of S6 heterozygous T cells
During the first 24 h after TCR stimulation in vitro, T
cells grow but do not divide. As discussed earlier, dele-
tion of one S6 allele decreased ribosome biogenesis in
stimulated S6wt/del T cells, but total protein production
and increase in cell size were comparable to control T
cells. In sharp contrast to normal growth, proliferation of
S6 heterozygous T cells in vitro was impaired. The lesion
in proliferation does not seem to result from reduced
translational capacity, but rather, activation of a p53-
dependent cell cycle checkpoint response. However, our
results cannot exclude an effect on translation of specific
mRNAs under these conditions with absolute certainty.
A p53-dependent checkpoint response to a defect
in ribosome biogenesis
Conditional deletion of both S6 alleles in CD4+ CD8+
thymocytes leads to a failure in T-cell development,
most likely as a result of activation of a p53-dependent
checkpoint, rather than defects in the protein transla-
tion. This conclusion is based on the fact that condi-
tional inactivation of p53 completely rescues S6del/del
thymocyte number. Surprisingly, even though ribosome
biogenesis is blocked in S6lox/lox/p53lox/lox/CD4-Cre+
thymocytes, the remaining ribosomes are sufficient to
allow T-cell development in the thymus. The rescued
thymocytes have a normal expression of CD3, CD4, and
CD8 markers, but it is not clear if they are normal by
other criteria. Although a direct effect of S6 on p53 ac-
tivation cannot be excluded, a p53-dependent check-
point response is most likely induced by defective ribo-
some biogenesis that cannot support proper execution of
the genetic program. S6lox/lox/p53lox/lox/CD4-Cre+ pe-
ripheral T cells are present in negligible numbers, prob-
ably as a consequence of translational deficiency that
results from degradation of remaining ribosomes with
time or inability to increase ribosome biogenesis after
stimulation. Bcl-2 expression partially rescues T-cell de-
velopment in S6lox/lox/CD4-Cre+ thymi. This suggests
that a p53-dependent checkpoint response could be at
least partially counteracted by Bcl-2. From our current
results, we can rule out the existence of a p53-dependent,
Bcl-2-independent apoptotic pathway(s) in S6del/del thy-
mocytes. Furthermore, a possible role of p53-dependent
nonapoptotic mechanisms in development of S6del/del
thymocytes will require further investigation. One S6
allele is not sufficient to allow production of normal lev-
els of S6 protein in TCR-stimulated peripheral T lym-
phocytes to support an increased rate of ribosome bio-
genesis, triggering a p53-dependent checkpoint response.
Our results are consistent with p53-dependent check-
point regulatory pathway activation by a defect in ribo-
some biogenesis. A similar p53-dependent defect in pro-
liferation was observed in the LAP3 mouse cell line in
which a defect in ribosome biogenesis was induced by
the expression of a dominant-negative mutant of Bop1, a
molecule that functions in ribosome biogenesis (Pestov
et al. 2001). In TCR-stimulated S6 heterozygous T lym-
phocytes, a predominant outcome of p53 activation is
induction of the p21 cell cycle inhibitor and, as a conse-
quence, inhibition of the cell cycle progression. In that
way, the cell cycle pace is adjusted to the capacity of the
cell to synthesize ribosomal protein S6 and ribosomes,
thereby preventing infidelity of the gene expression as a
consequence of reduced translational capacity. We are
currently testing the effect of p21 inactivation in vivo on
the proliferation of S6 heterozygous T cells.
It has been previously proposed that the nucleolus is a
stress sensor responsible for regulating the levels of p53,
which is elevated when nucleolar function is impaired
by different types of stresses (Rubbi and Milner 2003). In
normal cells, p53 protein expression is maintained at
low levels by MDM2-mediated ubiquitylation by
MDM2, export to the cytoplasm, and degradation by pro-
teasomes (Ryan et al. 2001). It is suggested that nucleolar
proteins are important regulators of p53 levels under
stress conditions in vitro (Olson 2004). The Arf protein,
which binds to MDM2 and negatively regulates its ac-
tivity, is under normal conditions sequestered in the
nucleolus (Tao and Levine 1999; Zhang and Xiong 1999;
Weber et al. 2000; Honda and Yasuda 1999). When the
nucleolus is disrupted, Arf is released from the nucleolus
to the nucleoplasm, where it binds to MDM2 and inhib-
its its activity and p53 degradation. Furthermore, Arf
was found to suppress processing of pre-rRNA by inter-
acting and inactivating the nucleolar protein B23, a
nuclease that carries out early pre-rRNA cleavage
(Itahana et al. 2003; Sugimoto et al. 2003). These findings
suggest that the Arf–B23 interaction may function in co-
ordinating cell growth with cell cycle progression. It has
been shown recently that L5, L11, and L23 ribosomal
proteins are released from the nucleolus following treat-
ments that inhibit ribosome biogenesis—such as starva-
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tion for nutrients or incubation with a low concentration
of actinomycin D in vitro—interact with MDM2, and
inhibit its activity toward p53 (Marechal et al. 1994;
Lohrum et al. 2003; Zhang et al. 2003; Bhat et al. 2004;
Jin et al. 2004). It has been proposed that they couple cell
growth to the cell cycle.
Here we demonstrate that deletion of the S6 gene,
which is coding for a component of the 40S ribosomal
subunit, induces a p53-dependent checkpoint response
in vivo, most likely through a defect in ribosome biogen-
esis. Although, we cannot formally rule out the possibil-
ity that altered protein synthesis is responsible for the
observed phenotypes, one argument against this is our
observation that the protein translation inhibitor puro-
mycin failed to up-regulate the protein levels of p53 in
TCR/CD28-stimulated T cells (data not shown). In the
same experiment, a low dose of actinomycin D and eto-
poside strongly induced p53. Impaired translation of
mRNAs encoding a key DNA damage repair or replica-
tion proteins could lead to DNA damage and activation
of a p53-dependent checkpoint. We did not observe any
increase in phosphorylation of ATM/ATR substrates
(phosphorylated SQ/TQ) and histone H2A.X (phospho-
Ser139) in TCR/CD28-stimulated S6wt/del T cells rela-
tive to S6wt/lox T cells using immunofluorescence analy-
sis (data not shown), suggesting that the DNA damage is
not responsible for activation of a p53-dependent check-
point in S6-deficient cells.
Ribosomal protein S6 is phosphorylated by S6 kinases
1 and 2 (S6K1/2) under growth-promoting conditions
(Volarevic and Thomas 2001). Is a p53-dependent prolif-
eration defect in TCR/CD28-stimulated S6wt/del T cells
the result of decreased levels of phosphorylated S6? Good
evidence against a positive role of S6 phosphorylation in
cellular proliferation has been provided by the recent
generation and analysis of knock-in mice, whose S6 con-
tains alanine substitutions at all five phosphorylatable
serines (Ruvinsky et al. 2005). These mice were indistin-
guishable from their wild-type littermates in develop-
ment, appearance, and weight. Interestingly, mouse em-
bryonic fibroblasts isolated from these mice proliferated
even better than the wild-type control, implying that a
decrease in S6 phosphorylation does not activate a p53-
dependent checkpoint. Consistent with this notion, we
have shown that rapamycin at concentrations that in-
hibit S6 phosphorylation does not induce the protein levels
of p53 in TCR/CD28-stimulated T cells (data not shown).
Inducible deletion of both S6 alleles in the liver abro-
gated cell division in response to hepatectomy, which
had been correlated with the inhibition of cyclin E ex-
pression (Volarevic et al. 2000). In contrast, TCR/CD28
stimulation of S6wt/del T cells normally up-regulated the
protein levels of cyclin E (data not shown). What is the
reason for such an apparent difference in these two mod-
els? It is possible that responses to deletion of one or two
S6 alleles are different. Certainly, this issue needs to be
addressed very carefully, before definitive conclusions
can be drawn.
What are the physiological consequences of this check-
point response? Since translation of specific mRNAs
depends on their affinity for ribosomes, it is possible that
mutations in the genes that decrease the number of
ribosomes can change the accuracy of translation, alter-
ing the precise execution of the genetic program (Lodish
1974; Mauro and Edelman 2002; Ruggero and Pandolfi
2003; Holland et al. 2004). Although increases in ribo-
some biogenesis have been correlated with a malignant
transformation in many instances, some ribosomal pro-
tein genes are suggested to be haploinsufficient tumor
suppressors in Zebrafish, Drosophila, and humans (Wat-
son et al. 1992; Stewart and Denell 1993; Draptchinskaia
et al. 1999; Amsterdam et al. 2004). To uncover the pos-
sible pathogenic potential of the S6wt/del mutation in T
cells, we will compare the incidence and severity of T-
cell lymphomas in S6wt/lox/p53wt/lox/CD4-Cre+ and
S6wt/wt/p53wt/lox/CD4-Cre+ mice and look for signs of
autoimmune phenomena.
In addition to a potential role in malignant transfor-
mation and autoimmunity, activation of a p53-depen-
dent checkpoint mechanism in response to defects in the
translational machinery might play an important role in
other fundamental biological processes such as senes-
cence and aging.
Materials and methods
Mice
S6lox/lox mice were produced previously (Volarevic et al. 2000).
CD4-Cre transgenic mice have been described earlier (Sawada et
al. 1994; Wolfer et al. 2001). Bcl-2 transgenic mice were ob-
tained from The Jackson Laboratory (Strasser et al. 1994). p53lox/lox
mice were created by Marino (Marino et al. 2000). Mice were
genotyped by PCR analysis of genomic DNA isolated from tail
tips using specific primers for the Cre recombinase (5-GTC
CAATTTACTGACCGTACAC-3 and 5-CTGTCACTTGGTC
GTGGCAGC-3); for the wild-type S6 allele (5-AGTGTAAC
TAGATAAATGAT-3 and 5-AGCCTTTTCTTTTAGCATA
C-3); for the floxed S6 allele (5-TGCTCCTGCCGAGAAAG
TATCCATCATGGC-3 and 5-GTGTTAACTCTTCTGCCA
GA-3); for the Bcl-2 transgene (5-GTCCCGCCCCTAACTC
CGCCCATCC-3 and 5-CCGCATCCCACTCGTAGCCCCT
CTG-3); for wild-type and floxed p53 allele (5-AAGGGGTAT
GAGGGACAAGG-3 and 5-GAAGACAGAAAAGGGGAG
GG-3); and for the deleted p53 allele (5-CACAAAAACAGGT
TAAACCCA-3 and 5-GAAGACAGAAAAGGGGAGGG-3)
(Marino et al. 2000). All mice were housed in conventional ani-
mal facilities of the Medical School, University of Rijeka.
Southern and Northern blot analyses
Genomic DNA isolated from thymi, purified spleen, and lymph
node T cells (R&D Systems) was genotyped by Southern blot
analysis of HindIII-restricted fragments using intron-specific
probes as described (Volarevic et al. 2000). Total RNA was iso-
lated from thymi and T cells stimulated in vitro using Trizol
(Invitrogen Life Technologies). RNA was separated on a 1%
agarose/formaldehyde gel and transferred to a Hybond N+ mem-
brane (Amersham Biosciences). Total RNA from thymi was hy-
bridized with S6 and L11 cDNA probes labeled with the Alk-
phos Direct Kit (Amersham) according to the manufacturer’s
instructions.
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Analysis of rRNA processing
For analysis of rRNA processing, T cells were stimulated for 20
h in vitro, starved for 15 min in methionine-free medium, la-
beled for 30 min with 25 µCi/mL [methyl-3H]methionine (Am-
ersham Biosciences), and then chased in medium containing
unlabeled methionine for indicated time periods. Total RNA,
isolated from the same number of mutant and control T cells,
was separated on a formaldehyde-agarose gel, blotted to the Hy-
bond N+ membrane, which was dried and treated with
EN3HANCE (New England Nuclear), and exposed to Kodak Bio-
Max MS film at −80°C (Sigma).
T-cell lysis and protein determination
S6wt/lox and S6wt/del T cells were collected prior to TCR/CD28
activation and at different time points after stimulation. The
same number of mutant and control T cells was dissolved in
RIPA buffer (50 mM tris-Cl at pH 7.5, 150 mM NaCl, 1 mM
EDTA, 1% NP-40, 0.25% Na-deoxycholate) containing protease
and phosphatase inhibitors (1 µg/mL leupeptin, 1 µg/mL apro-
tinin, 50 µg/mL PMSF, 1 mM Na3VO4, 1 mM NaF), lysed on ice
for 20 min, and centrifuged at 12,000 rpm for 30 min. Protein
concentration was determined by the Bio-Rad protein assay ac-
cording to the manufacturer’s instructions (Bio-Rad).
Western blot analysis
RIPA total protein lysates (30 µg per lane) were separated by
denaturing SDS-PAGE, transferred to Immobilon-P membrane
(Millipore), and probed with mouse monoclonal anti-S6 and
rabbit polyclonal anti-L7a antibodies and rabbit polyclonal anti-
L11, raised against a synthetic peptide CIGAKHRISKEEAMR-
WFQQK. Primary antibodies were detected by using HRP-con-
jugated secondary antibodies to rabbit and mouse immuno-
globulins (Santa Cruz Biotechnology) and the ECL Plus Western
Blotting Detection System (Amersham Biosciences).
Flow cytometry
Single-cell suspensions from thymi, spleen, and lymph nodes
were washed in PBS containing 2% FCS and 0.1% sodium azide
at 4°C, and 1 × 106 cells were stained with monoclonal antibod-
ies to CD3, CD45R (B220), CD4, CD8a, CD25, and CD69, all
purchased from BD Biosciences. Flow cytometry was performed
on a FACScan (Becton Dickinson) using Cell Quest software.
Ten-thousand events were collected.
Stimulation of T lymphocytes in vitro
T lymphocytes from lymph nodes and spleen were purified us-
ing columns from R&D Systems. The purity of T cells was
∼90%. Purified T cells were plated at 1 × 106 cells per well in a
flat-bottom six-well plate in RPMI 1640 medium containing
12% FCS, 2 mM L-glutamine, 5 µM 2-ME, 105 U/L penicillin,
0.1 g/L streptomycin, and 0.035 g/L gentamycin, and stimulated
with various concentrations of soluble anti-CD3 (145-2C11; BD
Biosciences) and anti-CD28 mAbs (37.51; BD Biosciences). In
some experiments, T cells were stimulated with the combina-
tion of soluble anti-CD3 and IL2 containing MLA 144 superna-
tant.
Intracellular cytokine staining
Lymphocytes stimulated in vitro with anti-CD3 and anti-CD28
antibodies were incubated with 10 µg/mL brefeldin A (Sigma)
during 3 h before harvesting. Cells were stained for T-cell sur-
face markers, fixed in 2% paraformaldehyde in PBS at 4°C, per-
meabilized with 0.1% saponin (Sigma), and stained with anti-
mouse IFN--FITC or anti-mouse IL-2 -FITC (BD Biosciences) in
0.05% saponin.
CFSE labeling
Cell division of stimulated T cells was analyzed using 2 mM
5-6-carboxyfluorescein diacetate succinimidyl ester (CFSE) la-
beling (Molecular Probes). This method is based on the approxi-
mately twofold decreases in CFSE fluorescence after each cell
division (Lyons and Parish 1994).
T cells from lymph nodes (1 × 107 cells/mL PBS) were stained
with CFSE at 37°C for 10 min in a CO2 incubator, washed twice
with PBS/2% FCS, and stimulated as described. For in vivo stud-
ies, 10 × 106 CFSE-labeled T cells were transferred intrave-
nously into nonirradiated syngenic wild-type hosts. CFSE in-
tensity was analyzed by flow cytometry.
BrdU staining and determination of apoptotic cells
For in vivo 5-bromo-2-deoxyuridine (BrdU) labeling studies,
mice were daily injected intraperitoneally with 100 µg/g of body
weight BrdU (Sigma) in 200 µL of PBS during indicated time
periods. BrdU uptake was measured in purified T cells from
lymph nodes (R&D Systems). In vitro stimulated T lympho-
cytes were incubated with 10 µM BrdU for 2 h and stained with
BrdU-FITC (BD Biosciences) according to the manufacturer’s
instructions. In brief, cells were washed with PBS, fixed in 70%
ethanol at 4°C, resuspended in 2N HCl/0.5% Triton X-100, in-
cubated for 30 min at room temperature, neutralized with 0.1 M
tetraborate (pH 8.5), rinsed in PBS containing 1% BSA and 0.5%
Tween 20, stained with the abovementioned anti-BrdU anti-
body, and then analyzed by FACS. For determination of apopto-
sis, T cells were stimulated, stained with propidium iodide at
different time points after stimulation, and analyzed by flow
cytometry. The percentage of sub-G1 cells was taken as the
percentage of apoptotic cells.
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